4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-[(3-methylphenyl)methyl]-1H,2H,3H,5H,6H,7H,8H-pyrido[1,2-c]pyrimidine-1,3-dione

Catalog No. :
ACVMDI994
CAS No. :
1775345-57-7
Molecular Formula :
C20H22N4O3
Molecular Weight :
366.42

IUPAC Name:4-(5-ethyl-1,2,4-oxadiazol-3-yl)-2-(3-methylbenzyl)-5,6,7,8-tetrahydro-1H-pyrido[1,2-c]pyrimidine-1,3(2H)-dione

4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-[(3-methylphenyl)methyl]-1H,2H,3H,5H,6H,7H,8H-pyrido[1,2-c]pyrimidine-1,3-dione structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(5-Ethyl-1,2,4-oxadiazol-3-yl)-2-[(3-methylphenyl)methyl]-1H,2H,3H,5H,6H,7H,8H-pyrido[1,2-c]pyrimidine-1,3-dione
IUPAC Name4-(5-ethyl-1,2,4-oxadiazol-3-yl)-2-(3-methylbenzyl)-5,6,7,8-tetrahydro-1H-pyrido[1,2-c]pyrimidine-1,3(2H)-dione
Molecular FormulaC20H22N4O3
Molecular Weight366.42
SMILESO=C1N2C(CCCC2)=C(C3=NOC(CC)=N3)C(N1CC4=CC=CC(C)=C4)=O
InChI KeySBQSPXMUIHUBAK-UHFFFAOYSA-N
Synonym4-(5-ethyl-1,2,4-oxadiazol-3-yl)-2-[(3-methylphenyl)methyl]-1H,2H,3H,5H,6H,7H,8H-pyrido[1,2-c]pyrimidine-1,3-dione;1H-Pyrido[1,2-c]pyrimidine-1,3(2H)-dione, 4-(5-ethyl-1,2,4-oxadiazol-3-yl)-5,6,7,8-tetrahydro-2-[(3-methylphenyl)methyl]-
CAS No.1775345-57-7

Synthetic Route by SureRoute

1. ACVMDI994 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVMDI994 route product structure diagram
    ACVMDI9941775345-57-7
Inquiry

2. ACVMDI994 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVMDI994 route product structure diagram
    ACVMDI9941775345-57-7
Inquiry

Comments (0)